Table 2.

Clinical characteristics of patients with fibrotic interstitial lung disease

Patient	Age	Gender	Treatment	FEV1 l	FEV1% predicted	Diagnosis	Smoking history: pack years/years of smoking cessation
A	63	Male	Esbriet	1.93	52.5	Fibrotic ILD	25 PY/15 Y cess
B	40	Female	No	No	No	Fibrotic ILD	n.d.
C	48	Male	No	n.d.	n.d.	Fibrotic ILD	0 PY
D	41	Female	No	n.d.	n.d.	Fibrotic ILD	0 PY
E	57	Male	Esbriet	1.5	43	Fibrotic ILD	35 PY/7 Y cess
F	65	Male	Cortisone 25 mg	1.1 l	39	Fibrotic ILD	70 PY/ 6Y cess
G	63	Male	Esbriet	1.8	48	Fibrotic ILD	30 PY/12Y cess
H	60	Male	Cortisone 7.5 mg	2.3	64	Fibrotic ILD	30 PY/15Y cess
I	54	Female	n.d.	n.d.	n.d.	Fibrotic ILD	n.d.
J	68	Male	No	n.d.	n.d.	Fibrotic ILD	0 PY
K	52	Female	Ofev	1.6	58	Fibrotic ILD	35 PY/2Y cess
L	60	Male	No	2.4	60	Fibrotic ILD	40 PY/5Y cess
M	56	Male	Esbriet	1.51	43	Fibrotic ILD	0 PY
N	52	Male	No	2.7	70	Fibrotic ILD	45 PY/2Y cess
O	65	Male	No	1.65	57	Fibrotic ILD	25 PY/20Y cess
P	59	Male	No	1.6	45	Fibrotic ILD	0 PY
Q	50	Male	Ofev	1.73	435	Fibrotic ILD	20 PY/12Y cess
R	68	Male	Ofev	1.3	41.4	Fibrotic ILD	0 PY
S	63	Male	Esbriet	1.99	53	Fibrotic ILD	30 PY/3Y cess
T	65	Male	Ofev	1.48	38	Fibrotic ILD	10 PY/15Y cess
U	59	Male	Cortisone 5 mg	0.93	26.2	Fibrotic ILD	10 PY/35Y cess

FEV1 forced expiratory volume at 1.0 s, FEV1% ratio of FEV1 to FVC, forced vital capacity, FEV1% predicted FEV1% of the patient divided by the average FEV1% in the equivalent population, ILD interstitial lung disease, PY pack year, Y cess years of smoking cessation, n.d. not determined